@article {CHARCHANTI333, author = {ANTONIA CHARCHANTI and PANAGIOTIS KANAVAROS and EFTHYMIOS KONIARIS and AGAPI KATAKI and GEORGIOS GLANTZOUNIS and NIKI J. AGNANTIS and ANNA C. GOUSSIA}, title = {Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis}, volume = {35}, number = {1}, pages = {333--339}, year = {2021}, doi = {10.21873/invivo.12264}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. Materials and Methods: Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. Results: According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p\<0.012) and intermediate (p\<0.003) fibrosis. Conclusion: In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis.}, issn = {0258-851X}, URL = {https://iv.iiarjournals.org/content/35/1/333}, eprint = {https://iv.iiarjournals.org/content/35/1/333.full.pdf}, journal = {In Vivo} }